📰 Cameron Durrant News
Page 4 - Cameron Durrant News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Cameron Durrant. Real-time updates on events, politics, business and more.
January 15, 2022
New York, NY (PRWEB) January 15, 2022 -- Every business relies on technology. That means every company is now vulnerable to cyberattacks. Most who get
January 4, 2022
Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called 'cytokine storm,' announced that Cameron Durrant
January 4, 2022
Press release content from Business Wire. The AP news staff was not involved in its creation.
January 3, 2022
03.01.2022 - Humanigen, Inc. (Nasdaq:HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, announced that a manuscript ... Seite 1
December 2, 2021
02.12.2021 - Humanigen, Inc. (Nasdaq:HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, announced today The Lancet ... Seite 1
December 2, 2021
Lenzilumab is a variant-agnostic therapeutic that targets the dysregulated host immune response, an approach which may be of greater value than targeting the virus in hospitalized patients1 Per
October 26, 2021
Ten most promising treatments for COVID-19 identified by the European Commission's independent experts as having "the highest potential impact on the pandemic" European Commission's independent
October 26, 2021
Press release content from Business Wire. The AP news staff was not involved in its creation.
October 25, 2021
Ten most promising treatments for COVID-19 identified by the European Commission's independent experts as having "the highest potential impact on the pandemic" European Commission's independent
October 22, 2021
An abstract showing tumor specific targeting at all known tumor sites in glioblastoma patients, with no normal tissue uptake of ifabotuzumab, from a Phase 1 study will be presented at EANM'21